TREACE MEDICAL CONCEPTS, INC.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

TMCI$4.88+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue	$50,214	$45,086	$150,171	$140,649
Cost of goods sold	10,508	8,954	30,820	27,862
Gross profit	39,706	36,132	119,351	112,787
Operating expenses
Sales and marketing	34,421	32,775	103,627	110,784
Research and development	4,680	4,963	15,740	15,379
General and administrative	16,281	13,528	48,216	42,108
Total operating expenses	55,382	51,266	167,583	168,271
Loss from operations	(15,676)	(15,134)	(48,232)	(55,484)
Interest income	634	1,067	2,250	3,978
Interest expense	(1,338)	(1,313)	(3,970)	(3,942)
Other income, net	92	20	344	206
Other non-operating income (expense), net	(612)	(226)	(1,376)	242
Net loss	$(16,288)	$(15,360)	$(49,608)	$(55,242)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	33	217	(14)	28
Comprehensive loss	$(16,255)	$(15,143)	$(49,622)	$(55,214)
Net loss per share, basic and diluted	$(0.26)	$(0.25)	$(0.79)	$(0.89)
Weighted-average shares used in computing net loss per share, basic and diluted	63,515,372	62,229,463	63,069,810	62,035,293

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.